These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 36404729)

  • 41. Novel immunotherapeutic approaches for hepatocellular carcinoma treatment.
    Busato D; Mossenta M; Baboci L; Di Cintio F; Toffoli G; Dal Bo M
    Expert Rev Clin Pharmacol; 2019 May; 12(5):453-470. PubMed ID: 30907177
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma.
    Chan LL; Chan SL
    Expert Opin Emerg Drugs; 2021 Mar; 26(1):39-52. PubMed ID: 33724135
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tyrosine kinase inhibitors as potential sensitizers of adoptive T cell therapy for hepatocellular carcinoma.
    Liang L; Wang X; Huang S; Chen Y; Zhang P; Li L; Cui Y
    Front Immunol; 2023; 14():1046771. PubMed ID: 36936932
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunotherapy of hepatocellular carcinoma: recent progress and new strategy.
    Li J; Xuan S; Dong P; Xiang Z; Gao C; Li M; Huang L; Wu J
    Front Immunol; 2023; 14():1192506. PubMed ID: 37234162
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Hepatocellular carcinoma immune microenvironment].
    Miao TG; Nan YM
    Zhonghua Gan Zang Bing Za Zhi; 2022 Sep; 30(9):923-930. PubMed ID: 36299184
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The State of Immunotherapy in Hepatobiliary Cancers.
    Ilyas FZ; Beane JD; Pawlik TM
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440865
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Radiation therapy in the era of immune treatment for hepatocellular carcinoma.
    Chen L; Zhang R; Lin Z; Tan Q; Huang Z; Liang B
    Front Immunol; 2023; 14():1100079. PubMed ID: 36742293
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oral chemotherapy for the treatment of hepatocellular carcinoma.
    Yamamoto S; Kondo S
    Expert Opin Pharmacother; 2018 Jun; 19(9):993-1001. PubMed ID: 29913090
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunotherapeutic Approaches for Treating Hepatocellular Carcinoma.
    Shen W; Chen Y; Lei P; Sheldon M; Sun Y; Yao F; Ma L
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291797
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.
    Chen Y; Hu H; Yuan X; Fan X; Zhang C
    Front Immunol; 2022; 13():896752. PubMed ID: 35757756
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immune System and Hepatocellular Carcinoma (HCC): New Insights into HCC Progression.
    Kotsari M; Dimopoulou V; Koskinas J; Armakolas A
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511228
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Synergistic Effect of Interventional Locoregional Treatments and Immunotherapy for the Treatment of Hepatocellular Carcinoma.
    Brandi N; Renzulli M
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239941
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Camrelizumab: an investigational agent for hepatocellular carcinoma.
    Xu B; Sun HC
    Expert Opin Investig Drugs; 2022 Apr; 31(4):337-346. PubMed ID: 34937475
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Paradigm shift in the treatment options of hepatocellular carcinoma.
    Su TH; Hsu SJ; Kao JH
    Liver Int; 2022 Aug; 42(9):2067-2079. PubMed ID: 34515412
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?
    Uson Junior PLS; Nagalo BM; Ahn DH; Bekaii-Saab T; Borad MJ
    Semin Liver Dis; 2021 May; 41(2):136-141. PubMed ID: 33957697
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunotherapy for hepatocellular carcinoma.
    Zongyi Y; Xiaowu L
    Cancer Lett; 2020 Feb; 470():8-17. PubMed ID: 31811905
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait.
    Rizzo A; Ricci AD; Brandi G
    Immunotherapy; 2021 Jun; 13(8):637-644. PubMed ID: 33820447
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Emerging Insights on Immunotherapy in Liver Cancer.
    Zhang Y; Zhang X; Kuang M; Yu J
    Antioxid Redox Signal; 2022 Dec; 37(16-18):1325-1338. PubMed ID: 35754339
    [No Abstract]   [Full Text] [Related]  

  • 59. Hepatocellular Carcinoma Immunotherapy.
    Sperandio RC; Pestana RC; Miyamura BV; Kaseb AO
    Annu Rev Med; 2022 Jan; 73():267-278. PubMed ID: 34606324
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 2,5-dimethylcelecoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-L1.
    Chen Z; Chen Y; Peng L; Wang X; Tang N
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.